Accordingly, treatment with anti-TIGIT exerts anti-tumor function by activating CD8+ T cells, enhancing the cytotoxicity effects and population of T cells against cancer [66, 122, 123, 133] (Fig. 4). This evidence concerns the gene CD8A and neoplasm.